Skip to main content

Table 2 Patient characteristics

From: Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)

  Patients (N = 216) in NEOZOTAC
Median age, years (range)   49.5 (28–70)
Median BMI, kg/m2 (range)   26.2 (18.3–42.0)
Clinical T stage cT1 or cT2 123 (56.9 %)
  cT3 or cT4 93 (43.1 %)
Clinical N stage cN0 101 (46.8 %)
  cN+ 115 (53.2 %)
Tumor type Ductal 128 (59.3 %)
  Lobular 38 (17.6 %)
  Other 18 (8.4 %)
  Unknown 32 (14.8 %)
HR status ER+ and/or PR+ 180 (83.3 %)
  ER– and PR– 36 (16.7 %)
Allocated treatment TAC 109 (50.5 %)
  TAC + ZA 107 (49.5 %)
pCR breast and LN Yes 25 (11.6 %)
  No 184 (85.2 %)
  Unknown 7 (3.2 %)
MP breast 1 33 (15.3 %)
  2 56 (25.9 %)
  3 41 (19.0 %)
  4 42 (19.4 %)
  5 35 (16.2 %)
  Unknown 9 (4.2 %)
  1. BMI body mass index, ER estrogen receptor, HR hormone receptor, LN lymph nodes, MP Miller and Payne, pCR pathologic complete response, PR progesterone receptor, TAC docetaxel, doxorubicin, and cyclophosphamide, ZA zoledronic acid